Last reviewed · How we verify

IncobotulinumtoxinA (75 Units) — Competitive Intelligence Brief

IncobotulinumtoxinA (75 Units) (IncobotulinumtoxinA (75 Units)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Botulinum toxin. Area: Neurology, Dermatology, Aesthetics.

phase 3 Botulinum toxin SNAP-25 (synaptosome-associated protein of 25 kDa) Neurology, Dermatology, Aesthetics Small molecule Live · refreshed every 30 min

Target snapshot

IncobotulinumtoxinA (75 Units) (IncobotulinumtoxinA (75 Units)) — Merz Pharmaceuticals GmbH. IncobotulinumtoxinA blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
IncobotulinumtoxinA (75 Units) TARGET IncobotulinumtoxinA (75 Units) Merz Pharmaceuticals GmbH phase 3 Botulinum toxin SNAP-25 (synaptosome-associated protein of 25 kDa)
OnabotulinumtoxinA 50 UNT [Botox Cosmetic] OnabotulinumtoxinA 50 UNT [Botox Cosmetic] Amir Moradi MD, MBA marketed Botulinum toxin SNARE complex (synaptosome-associated protein)
Clostridium Botulinum Toxin Type A Clostridium Botulinum Toxin Type A Daewoong Pharmaceutical Co. LTD. marketed Neurotoxin; botulinum toxin SNAP-25 (synaptosome-associated protein of 25 kDa)
NT 201 NT 201 Merz Aesthetics GmbH marketed Botulinum toxin type A SNARE complex (acetylcholine release machinery)
PrabotulinumtoxinA-Xvfs PrabotulinumtoxinA-Xvfs Lupo Center for Aesthetic and General Dermatology marketed Botulinum toxin type A SNARE complex (acetylcholine release machinery)
OnabotulinumtoxinA (ONA) OnabotulinumtoxinA (ONA) Hexsel Dermatology Clinic marketed Botulinum toxin SNAP-25 (synaptosome-associated protein of 25 kDa)
NAFT500 (adult) NAFT500 (adult) Merz North America, Inc. marketed Botulinum toxin type A SNARE complex (acetylcholine release machinery)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Botulinum toxin class)

  1. Galderma R&D · 2 drugs in this class
  2. Hexsel Dermatology Clinic · 2 drugs in this class
  3. Seoul National University Hospital · 2 drugs in this class
  4. University of Utah · 2 drugs in this class
  5. Daewoong Pharmaceutical Co. LTD. · 2 drugs in this class
  6. EuBiologics Co.,Ltd · 1 drug in this class
  7. Allergan · 1 drug in this class
  8. GlaxoSmithKline · 1 drug in this class
  9. Beth Israel Deaconess Medical Center · 1 drug in this class
  10. Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IncobotulinumtoxinA (75 Units) — Competitive Intelligence Brief. https://druglandscape.com/ci/incobotulinumtoxina-75-units. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: